Radiolabelled peptides in diagnosis and therapy: an introduction

Al‐Nahhas, Adil; Fanti, Stefano

doi:10.1007/s00259-012-2064-5

Cited by 23 publications

(20 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sensitivity of 111 In-pentetreotide scintigraphy has been well documented and is generally >75% for gastroenteropancreatic and bronchial tumors [18]. Since 2000, the approach to the molecular imaging of NETs has been revolutionized by the introduction of PET with the 68 Ga-labeled octreotide derivatives DOTATOC, DOTATATE and DOTANOC ( 68 Ga-SSA-PET/CT) [19,20]. The overall sensitivity of 68 Ga-SSA-PET/CT for NETs is >90%, while the specificity ranges from 92 to 98% [21,22,23].…”

Section: Techniquesmentioning

confidence: 99%

The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

et al. 2014

View full text Add to dashboard Cite

Diagnostic imaging plays a pivotal role in the diagnosis, staging, treatment selection and follow-up for neuroendocrine tumors. The available diagnostic strategies are morphologic imaging, including computed tomography, magnetic resonance imaging (MRI) and ultrasound techniques, and molecular imaging, including scintigraphy with ¹¹¹In-pentetreotide and positron emission tomography with ⁶⁸Ga-DOTA-peptides, ¹⁸F-DOPA and ¹¹C-5-HTP. A combination of anatomic and functional techniques is routinely performed to optimize sensitivity and specificity. The introduction of diffusion-weighted MRI and dynamic contrast-enhanced techniques represents a promising advance in radiologic imaging, whereas new receptor-binding peptides, including somatostatin agonists and antagonists, represent the recent most favorable innovation in molecular imaging. Future development includes the short-term validation of these techniques, but in extension also a more comprehensive multilevel integration of biologic information pertaining to a specific tumor and patient, possibly encompassing genomic considerations, currently evolving as a new entity denoted ‘precision medicine'. The ideal is a diagnostic sequence that captures the global status of an individual's tumor and encompasses a multidimensional characterization of tumor location, metabolic performance and target identification. To date, advances in imagery have focused on increasing resolution, discrimination and functional characterization. In the future, the fusion of imagery with the parallel analysis of biological and genomic information has the potential to considerably amplify diagnosis.

show abstract

Section: Techniquesmentioning

confidence: 99%

The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Furthermore, its physical half-life of 68 min renders it compatible with the in vivo pharmacokinetics of many peptides and antibody fragments. Thus, the application of 68 Ga-labeled peptides for cancer imaging has gained considerable interest in recent years [14,15]. One of the main advantages of 68 Ga is that it can be used as the diagnostic analogue of many trivalent radionuclides, for which the coordination chemistry is fully developed.…”

mentioning

confidence: 99%

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Bouziotis

Stellas

Thomas

et al. 2017

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim: The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 (68Ga). Materials & methods: AGuIX@NODAGA nanoparticles were labeled with 68Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging. Results: 68Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts. Metabolite assessment in serum, urine and tumor samples showed that 68Ga-AGuIX@NODAGA remains unmetabolized up to at least 60 min postinjection. Conclusion: This study demonstrates that 68Ga-AGuIX@NODAGA can be used as a dual-modality PET/MR imaging agent with passive accumulation in the diseased area, thus showing great potential for PET/MR image-guided radiation therapy.

show abstract

“…Lesions larger than 1 cm in size and/or regional nodal involvement would warrant for metastatic survey with imaging modalities, particularly with somatostatin receptor PET-CT. It is also suggested that receptor imaging with PET-CT could be highly sensitive for detecting regional lymph node metastases as well, similar to its performance in the detection of distant metastases [2][3][4].…”

Section: Clinical Presentations Of Neuroendocrine Tumour and The Diagmentioning

confidence: 99%

“…Furthermore, recent years have witnessed the remarkable success of PET using 68 Ga-labelled somatostatin analogues (e.g. DOTA-TOC/NOC/TATE) as a highly sensitive technique in NETs for disease staging, monitoring and assessment of somatostatin receptor status [1][2][3][4][5][6][7], which has brought about a revolutionary change in the diagnostic approach to these tumours. Thus, it is important to conduct a critical appraisal of the pros and cons of each modality and generate a consensus opinion on the preferential use of one modality over the other in a specific clinical setting.…”

Section: Introductionmentioning

confidence: 99%

Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with 68Ga-labelled somatostatin analogues

Basu¹

2012

Nuclear Medicine Communications

View full text Add to dashboard Cite

Radiolabelled peptides in diagnosis and therapy: an introduction

Cited by 23 publications

References 12 publications

The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with 68Ga-labelled somatostatin analogues

Contact Info

Product

Resources

About

Radiolabelled peptides in diagnosis and therapy: an introduction

Cited by 23 publications

References 12 publications

The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

68 Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with 68Ga-labelled somatostatin analogues

Contact Info

Product

Resources

About

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy